Why the study?
Does KCNH2 mutation or pharmacologic block disrupt vasculogenesis and cardiogenesis in embryonic models?
Does KCNH2 mutation or pharmacologic block disrupt vasculogenesis and cardiogenesis in embryonic models?
Loss of function of KCNH2 via mutation or pharmacologic block disrupts embryonic cardiogenesis and vasculogenesis, suggesting potential teratogenic risks of IKr-blocking medications.
May warrant caution with IKr blockers in early pregnancy; leaves open human translation of embryonic KCNH2 effects.
No takes yet. Share an insight, caveat, or question.
Teng et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: